Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Apr;36(4):254-255.
doi: 10.1089/AID.2019.0253. Epub 2020 Mar 9.

Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy

Babafemi O Taiwo  1 , Miguel E Quiñones-Mateu  2 , Kimberly Smith  3 , Lu Zheng  4 , Roy Gulick  5 , Amesika N Nyaku  6 , Paul E Sax  7 , Belinda Ha  3 , Johnstone Kumwenda  8 , Maxine Olefsky  4 , Catherine Godfrey  9 , Carole Wallis  10
Affiliations
Comment

Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy

Babafemi O Taiwo et al. AIDS Res Hum Retroviruses. 2020 Apr.
No abstract available

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Minority drug-resistant variants detected in participants with virologic failure in AIDS Clinical Trials Group A5353.
See this image and copyright information in PMC

Comment on

References

    1. Boffito M, Waters L, Cahn P, et al. : Perspectives on the barrier to resistance for dolutegravir + lamivudine, a 2-drug antiretroviral therapy for HIV-1 infection. AIDS Res Hum Retroviruses 2019;36:13–18 - PMC - PubMed
    1. Taiwo BO, Zheng L, Stefanescu A, et al. : ACTG A5353: A pilot study of dolutegravir plus lamivudine for initial treatment of human immunodeficiency virus-1 (HIV-1)-infected participants with HIV-1 RNA <500000 Copies/mL. Clin Infect Dis 2018;66:1689–1697 - PMC - PubMed
    1. Gibson RM, Meyer AM, Winner D, et al. : Sensitive deep sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism. Antimicrob Agents Chemother 2014;58:2167–2185 - PMC - PubMed
    1. Cahn P, Madero JS, Arribas JR, et al. : Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): Week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet 2019;393:143–155 - PubMed